Abstract Background Psychedelics have long been explored as potential treatments for mental illnesses. Since the mid-20th century, clinical trials of psychedelics such as LSD for depression and anxiety in terminally ill patients have been conducted. In the 21st century, revived and accelerated efforts to promote the proper use of psychedelics in the medical ...
Abstract Background Major depressive disorder (MDD) is a multifactorial and heterogeneous disorder that affects around 280 million individuals worldwide, with approximately 80 million experiencing treatment-resistant depression (TRD). Neuronal hypotrophy and axon hypomyelination in the prefrontal cortex (PFC) are hallmark features of MDD, highlighting the ne...
Abstract Background Obsessive-compulsive disorder (OCD) is associated with significant personal suffering and functional impairment. At least a third of OCD patients do not respond to conventional treatments. There is a substantial anecdotal literature suggesting that psychedelic agents, specifically psilocybin and psilocybin-containing psychedelic mushroom ...
Abstract Background Despite the widespread availability of multiple antidepressant treatments, depression remains a common and sometimes debilitating disorder. A significant proportion of patients with major depressive disorder fail two or more antidepressant treatments and are considered to have treatment-resistant depression (TRD). Recent attention has tur...
There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating Disorders (“MED-FED”) survey investigated the lived experience of adults with EDs regarding their prescription and non-prescription drugs use. Psychedelic drugs were highly rated in this survey for their impact o...
This study examines the relationship between psilocybin reforms and usage patterns of prevalent psychedelics in the United States. Given decriminalization efforts in several cities and legalization in Oregon, the author analyzes drug use panel data from University of Michigan's Monitoring the Future project to assess changes in self-reported use of psilocybi...
Perception of visual contrast depends on the surrounding spatial context. Typically, the salience of a central target is reduced by a high contrast surrounding stimulus, an effect known as surround suppression. Although this phenomenon is well-studied, the role of specific neurotransmitter systems during surround suppression in human vision remains unclear. ...
BACKGROUND: Recent regulatory changes in Australia have approved 3,4-methylenedioxymethamphetamine for treating post-traumatic stress disorder and psilocybin for treatment-resistant depression. However, limited data exists on Australian mental healthcare providers' attitudes, knowledge and readiness to implement with psychedelic-assisted psychotherapy. METHO...
Background: Although classic psychedelic trials show therapeutic potential, the limited diversity of participants raises concerns about generalizability and safety. Aims: This study assesses the representation of race, ethnicity, and sex in interventional clinical trials of psilocybin and lysergic acid diethylamide (LSD) to evaluate disparities in participan...
Innovative therapies, such as psilocybin-assisted psychotherapies, hold great promises for treating anxiety, depression, and various other mental health disorders, addressing some of the challenges faced by conventional psychiatric medicine. This study focuses on developing and validating an HPLC-DAD methodology for detecting psilocybin and psilocin in extra...
Background Recent studies have suggested that psychedelics such as lysergic acid diethylamide (LSD) and psilocybin might benefit patients with mental illness. This revival calls for revisiting the field’s past experiences with these agents. From 1960 to 1973, many patients were treated with LSD and/or psilocybin at the Department of Psychiatry at Frederiksbe...
Recent advancements in the study of psilocybin and its active metabolite psilocin have highlighted their unique psychedelic properties and potential therapeutic applications, particularly in the rapid and sustained treatment of depression. However, the potent acute psychedelic effects of psilocybin necessitate a deeper understanding of the neural mechanisms ...
Psychedelic-assisted therapies and ketamine are two modalities gaining attention in psychiatry for treating conditions such as depression, PTSD, and substance use disorders. However, perceptions of these treatments vary globally. This study explores the familiarity, attitudes, and perceptions of Jordanian physicians and medical students toward psychedelic su...
Abstract Psychedelic drug use is experiencing a global resurgence, both in clinical research and community settings. This paper presents a comprehensive public health analysis of the naturalistic use of psychedelics-defined as use outside clinical or research environments. Drawing on a review of 104 peer-reviewed articles, this analysis evaluates the mental,...
ABSTRACT Three novel 14 C-labelled isotopologues of the psychoactive agents psilocin, psilocybin and 5-methoxy- N, N -dimethyltryptamine (5-MeO-DMT) were synthesised, all labelled at the 2-position of the indole. The syntheses involved incorporating the 3-dimethylaminoethyl substituent common to all three substances onto a 4- or 5-substituted indole intermed...
BACKGROUND: Psilocybin-assisted psychotherapy (PAP) is a promising treatment for various psychiatric disorders. However, the exact biological and psychological mechanisms of action of PAP remain to be determined. Examining predictors of PAP outcomes may help identify necessary processes for positive treatment outcomes. Mystical experiences are considered a k...
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder marked by motor symptoms due to dopaminergic degeneration and non-motor symptoms such as depression, anxiety, and cognitive impairment, which significantly affect patients' quality of life. Traditional dopaminergic therapies address motor symptoms but offer limited efficacy for neuropsychia...
Serotonergic psychedelics alter self-boundaries and can induce out-of-body experiences (OBEs)-the sense of being located outside one’s physical body. While OBEs also occur in clinical conditions and can be experimentally induced, their neural basis under psychedelics remains underexplored. In an open-label, baseline-controlled MRI study of 62 healthy adults ...
